] . Pre-eclampsia. Lancet. 2010;376(9741):631-44. 
(809.94 KB)
(809.94 KB). Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. (280.12 KB)
(280.12 KB). Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62. (178.71 KB)
(178.71 KB). The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120. (322.85 KB)
(322.85 KB). Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529. (298.54 KB)
(298.54 KB). Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714. (383.37 KB)
(383.37 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB). Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27. (201.46 KB)
(201.46 KB). Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48. (309.47 KB)
(309.47 KB). The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8. (370.8 KB)
(370.8 KB). Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809. (269.78 KB)
(269.78 KB). Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29(7):551-6. (194.2 KB)
(194.2 KB). Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29(7):551-6. (194.2 KB)
(194.2 KB). Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach. Int J Gynaecol Obstet. 2012;119 Suppl 1:S30-S34. (112.74 KB)
(112.74 KB). The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81. (233.18 KB)
(233.18 KB). Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926. (322.96 KB)
(322.96 KB). An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71. (232.97 KB)
(232.97 KB). Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527. (2 MB)
(2 MB). Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6. (660.26 KB)
(660.26 KB). Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8. (85.31 KB)
(85.31 KB). Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223. (529.81 KB)
(529.81 KB). PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202. (183.96 KB)
(183.96 KB). Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351. (447.63 KB)
(447.63 KB). Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4. (189.28 KB)
(189.28 KB). Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932-42. (529.57 KB)
(529.57 KB). Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152. (834.74 KB)
(834.74 KB). 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481. (706.24 KB)
(706.24 KB). Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform. 2014;18(6):1857-64. (300.31 KB)
(300.31 KB). Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014;36(12):1055-1064. (1.57 MB)
(1.57 MB). Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12):e113715. (359.44 KB)
(359.44 KB). Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG. 2014;121(8):951-7. (118.31 KB)
(118.31 KB). Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163. (1.42 MB)
(1.42 MB). Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220. (158.15 KB)
(158.15 KB). Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62. (317.15 KB)
(317.15 KB). Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454. (486.35 KB)
(486.35 KB). A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589. (353.97 KB)
(353.97 KB). Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877. (1021.64 KB)
(1021.64 KB). Are long-term health risks of pre-eclampsia and intrauterine growth restriction really the same?. BJOG. 2015;122(13):1824. (33.63 KB)
(33.63 KB). Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24. (1.11 MB)
(1.11 MB). Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21. (505.41 KB)
(505.41 KB). Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol. 2015;46(2):182-90. (349.22 KB)
(349.22 KB). Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76. (1.88 MB)
(1.88 MB). The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. Pregnancy Hypertens. 2015;5(4):273-9. (318.08 KB)
(318.08 KB). Genome-wide DNA methylation identifies trophoblast invasion-related genes: Claudin-4 and Fucosyltransferase IV control mobility via altering matrix metalloproteinase activity. Mol Hum Reprod. 2015;21(5):452-65. (1007.58 KB)
(1007.58 KB). The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57. (227.04 KB)
(227.04 KB). Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61. (463.16 KB)
(463.16 KB). Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8. (515.75 KB)
(515.75 KB). Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87. (362.1 KB)
(362.1 KB). Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347. (549.75 KB)
(549.75 KB)